Inner workings of virus responsible for rare skin cancer

September 15, 2011

Scientists at the University of Pittsburgh Cancer Institute have begun to uncover how the virus that causes most Merkel cell carcinoma – a rare and aggressive skin cancer – operates, meaning that a rational chemotherapeutic target for this cancer could be developed in the near future.

Patrick Moore, M.D., M.P.H., an American Cancer Society professor in the laboratory of Yuan Chang and Patrick Moore at the University of Pittsburgh Cancer Institute in Pittsburgh, Pa., presented these study results at the Second AACR International Conference on Frontiers in Basic Cancer Research, held here Sept. 14-18, 2011.

Merkel is a rare and highly aggressive cancer, the incidence of which has increased fourfold during the last 20 years, particularly in immunosuppressed populations, according to Moore.

"Unfortunately, Merkel cell carcinoma is difficult to treat and clinical trials of chemotherapeutics have been disappointing in affecting clinical course and survival," he said. "Discovery of the molecular cause for this cancer provides opportunities to directly target the cellular pathways that are perturbed by the virus."

In 2008, Moore and colleagues discovered Merkel cell polyomavirus (MCV), the virus that causes most Merkel cell carcinoma. Polyoma refers to the ability of some members of this family to produce multiple tumors in animal models. Their laboratory previously discovered the herpes virus that causes Kaposi's sarcoma, cancer that commonly occurs in patients with AIDS.

"MCV is the first polyomavirus to be consistently associated with human cancer, and is believed to cause 80 percent of Merkel cell ," Moore said.

MCV is a natural component of the human skin and is usually harmless, according to Moore. In fact, most adults carry the virus in some part of their skin cells. However, if someone becomes immunodeficient and the virus undergoes specific mutations, then it can generate .

In the three years since they discovered MCV, this group has also discovered several of the unique characteristics of the virus. Most recently, their studies showed that MCV small T antigen protein is a new oncogene that can contribute to abnormal cell growth in both rodent and human cells. In addition, MCV does not act the same as other polyomaviruses that have served as classic models of cancer. These other polyomaviruses depend on viral interaction with the enzyme PP2A and heat-shock proteins; MCV interacts with them, but does not depend on them.

Moore and colleagues found that MCV could still cause the abnormal cell growth even after abolishing PP2A and heat-shock protein binding sites. The researchers hope to develop treatments that will directly target the cellular pathways affected by this .

"We are making headway on this approach now and have tested more than 1,350 drugs to identify better methods to treat this virus-caused ," Moore said.

Explore further: Cancer researchers find key oncoprotein in Merkel cell carcinoma

Related Stories

Cancer researchers find key oncoprotein in Merkel cell carcinoma

August 15, 2011
Researchers at the University of Pittsburgh Cancer Institute (UPCI) have identified the oncoprotein that allows a common and usually harmless virus to transform healthy cells into a rare but deadly skin cancer called Merkel ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.